Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Presentation / Abstract • Phase 2
Company profile
Cellectar Biosciences, Inc.
Pipeline3 assets
- Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic; iodine-131 beta emitter / OncologyRelapsed/refractory Waldenström macroglobulinemiaPhase 2 pivotalcompletedRelapsed/refractory multiple myelomaPhase 2bongoingCNS lymphomaPhase 2bongoing
- CLR 121125CLR 125 / tumor cell nucleus via phospholipid ether platform / PLE radioconjugate; iodine-125 Auger emitter / OncologyRelapsed/refractory triple-negative breast cancerPhase 1bongoing
- CLR 121225CLR 225 / tumor cells via phospholipid ether platform / PLE radioconjugate; actinium-225 alpha emitter / OncologyPancreatic cancerPhase 1planned
Latest news11 items
All newsCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Presentation / Abstract • Phase 2ASCO poster presentation Mon, Jun 1, 2026, 9:00 AM CDT
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Presentation / Abstract • Phase 2ASCO poster presentation Mon, Jun 1, 2026, 9:00 AM CDT